A pair of peptides inhibits seeding of the hormone transporter transthyretin into amyloid fibrils by Saelices, Lorena et al.
A pair of peptides inhibits seeding of the hormone
transporter transthyretin into amyloid fibrils
Received for publication,August 7, 2018, and in revised form, January 22, 2019 Published, Papers in Press, February 7, 2019, DOI 10.1074/jbc.RA118.005257
X Lorena Saelices‡, X Binh A. Nguyen‡, Kevin Chung‡, Yifei Wang‡, Alfredo Ortega‡, X Ji H. Lee‡, Teresa Coelho§,
Johan Bijzet¶, Merrill D. Benson, and X David S. Eisenberg‡1
From the ‡Departments of Biological Chemistry and Chemistry and Biochemistry, Howard HughesMedical Institute, UCLA-DOE
Institute, Molecular Biology Institute, UCLA, Los Angeles, California 90095-1570, the §Neurophysiology Department and Corino de
Andrade Unit, Hospital Santo Anto´nio, Centro Hospitalar do Porto, Porto 4099-001, Portugal, the ¶Department of Rheumatology
and Clinical Immunology, University Medical Center Groningen, Groningen, 9713 GZ, The Netherlands, and the Department of
Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202
Edited by Paul E. Fraser
The tetrameric protein transthyretin is a transporter of reti-
nol and thyroxine in blood, cerebrospinal fluid, and the eye, and
is secreted by the liver, choroid plexus, and retinal epithelium,
respectively. Systemic amyloid deposition of aggregated tran-
sthyretin causes hereditary and sporadic amyloidoses. A com-
mon treatment of patientswithhereditary transthyretin amyloi-
dosis is liver transplantation. However, this procedure, which
replaces the patient’s variant transthyretinwith theWTprotein,
can fail to stop subsequent cardiac deposition, ultimately re-
quiring heart transplantation. We recently showed that pre-
formed amyloid fibrils present in the heart at the time of surgery
can template or seed further amyloid aggregation of native tran-
sthyretin. Here we assess possible interventions to halt this
seeding, using biochemical andEMassays.We found that chem-
ical or mutational stabilization of the transthyretin tetramer
does not hinder amyloid seeding. In contrast, binding of the
peptide inhibitor TabFH2 to ex vivo fibrils efficiently inhibits
amyloid seeding by impeding self-association of the amyloid-
driving strands F and H in a tissue-independent manner. Our
findings point to inhibition of amyloid seeding by peptide inhib-
itors as a potential therapeutic approach.
Transthyretin amyloidosis (ATTR)2 is a fatal disease caused
by the abnormal aggregation of the protein transthyretin
(TTR). TTR, a transporter of retinol and thyroxine in blood,
cerebrospinal fluid, and the eye, is secreted by the liver, choroid
plexus, and retinal epithelium, respectively. TTR amyloid
deposits are found in virtually every organ of ATTR patients,
but the heart and nerves are often the first to fail. Although
more than 140 known hereditary mutations in the ttr gene
result in an early onset of the disease,WTTTR is foundnot only
co-depositing with mutant TTR in hereditary ATTR cases but
also in sporadic cases in which only WT TTR is present. WT
ATTR, or senile systemic amyloidosis, manifests as an age-re-
lated disease, and is often overlooked and underdiagnosed
(1, 2).
The current standard of care for hereditary cases is liver
transplantation, which does not always cure the condition.
Through this procedure, most of the circulatingmutant TTR is
replaced with the WT form that is secreted by the implanted
liver. However, this surgery is not sufficient to stop amyloid
cardiac deposition in many patients who require heart trans-
plantation a few years later. Our recent studies suggest the rea-
son for such continued cardiomyopathy: pre-formed TTR
fibrils present in cardiac tissues of ATTR patients at the time of
surgery have the capacity to catalyze or seed fibril aggregation of
WT TTR that is secreted by the implanted liver (3).
The stabilization of the functional nonamyloidogenic formof
transthyretin is currently under clinical assessment. The func-
tional and most abundant form of TTR is tetrameric, with a
hydrophobic central tunnel that binds thyroxine. Kelly and col-
leagues (4) have established that conversion of native transthy-
retin to amyloid fibrils is preceded by dissociation of tetrameric
TTR to monomers, which then undergo a conformational
change and form fibrils. Based on this premise, extensive bio-
chemical studies have led to the discovery of compounds such
as tafamidis and diflunisal that bind within the hydrophobic
central tunnel of TTR and stabilize the native structure, inhib-
iting its aggregation in vitro (5–7). These two ligands stabilize
tetrameric transthyretin in vivo and delay the progression of
disease in many patients. However, the efficacy of these ligands
is reduced when administered at late stages of the disease (8, 9).
In our recent studies, we have developed and optimized pep-
tide inhibitors that are designed to cap the tip of TTR fibrils and
block further amyloid aggregation (3, 10). This structure-based
drug design strategy started with the identification of two amy-
loid-driving segments of transthyretin: -strands F and H (10).
We then determined the structures of the two segments in their
amyloid state and designed peptide inhibitors that block self-
This work was supported by Amyloidosis Foundation Grant 20160759 and
20170827, National Institutes of Health Grant R01-AG048120, and The
Howard Hughes Medical Institute. The authors and UCLA have filed an
international patent application for the TTR inhibitors (number PCT/US17/
40103). D. S. E. is an advisor and equity holder of ADRx, Inc. L. S. is a con-
sultant of ADRx, Inc. The content is solely the responsibility of the authors
and does not necessarily represent the official views of the National Insti-
tutes of Health.
1 To whom correspondence should be addressed: Howard Hughes Medical
Institute, UCLA-DOE Institute, Departments of Biological Chemistry and
Chemistry and Biochemistry, Molecular Biology Institute, Box 951570,
UCLA, Los Angeles, CA 90095-1570. Tel.: 310-825-3754; E-mail: david@
mbi.ucla.edu.
2 The abbreviations used are: ATTR, transthyretin amyloidosis; TTR, transthy-
retin; ThT, thioflavin T; BisTris, 2-[bis(2-hydroxyethyl)amino]-2-(hydro-
xymethyl)propane-1,3-diol.
croARTICLE
6130 J. Biol. Chem. (2019) 294(15) 6130–6141
© 2019 Saelices et al. Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc.
association and protein aggregation in vitro. This first genera-
tion of inhibitors was further optimized in a second study (3).
Amyloid seeding offers a potential therapeutic target to be
explored. Clinical observations indicate that amyloid seeding
greatly contributes to ATTR pathogenesis (11). In our previous
study, we found that tetramer stabilizers do not inhibit amyloid
seeding catalyzed by amyloid fibrils extracted from an ATTR-
D38A patient (3). In contrast, our peptide inhibitors halted this
process. Here we expand our studies by evaluating the efficacy
of both tetramer stabilization andpeptide inhibitors in blocking
amyloid seeding of ATTR fibrils extracted from affected tissue
of several types.
Results
Tetramer stabilization by ligands does not inhibit TTR amyloid
formation induced by ATTR-D38A ex vivo seeds
We previously found that the presence of tafamidis or difl-
unisal at 180 M is not sufficient to prevent amyloid seeding
of WT TTR catalyzed by ATTR fibrils extracted from the
explanted heart of an ATTR-D38A patient (3). Although
ATTR-D38A patients manifest slow progressive polyneuropa-
thy and autonomic symptoms similar to the most common
form of hereditary ATTR, ATTR-V30M, they also develop car-
diac dysfunction (12). Here we expand our previous study by
evaluating the effect of these ligands at various concentrations.
We first confirmed the ability of tafamidis and diflunisal to
inhibit protein aggregation in the absence of seeds. Consistent
with previous studies, we found that both tafamidis and difluni-
sal efficiently inhibitWTTTR aggregation in vitro under acidic
conditions in the absence of seeds (Fig. 1, a and b) (5–7). For
these aggregation assays, we incubated 1mg/ml of recombinant
WT TTR with increasing amounts of stabilizers at pH 4.3 and
monitored protein aggregation both by absorbance at 400 nm
and immunodot blot of the insoluble fraction, as we previously
described (10). After 4 days in the absence of inhibitor, virtually
the total amount of TTR present was converted to aggre-
gates. In the presence of either tafamidis or diflunisal, TTR
aggregation was diminished in a dose-dependent manner
(Fig. 1, a and b).
We next studied the effect of various concentrations of
tafamidis and diflunisal on protein aggregation in the presence
of ATTR-D38A ex vivo seeds. In our previous study, we ob-
served that the addition of fibril seeds extracted from ATTR
cardiac tissue accelerates aggregation not only of WT TTR at
pH 4.3 but also monomeric TTR under physiological condi-
tions (3). Additionally, we tested the effect of tafamidis and
diflunisal at 180 M on amyloid seeding and found that this
concentration was not sufficient to hinder the process. Here we
evaluate the effect of these ligands at various concentrations
(Fig. 1, c–f). For this assay, we incubated 0.5 mg/ml of recom-
binant WT TTR with 30 ng/l of ATTR-D38A ex vivo seeds
and increasing amounts of ligands.Wemonitored fibril forma-
tion for 24 h by thioflavin T fluorescence (ThT), by immunodot
blot of the insoluble fraction (Fig. 1, c–f), and by protein quan-
tification of insoluble fractions (Fig. 1g), as we previously
described (10). We found that these ligands did not reduce or
delay seeded fibril formation even at ligand concentrations that
resulted in full inhibition of unseeded TTR aggregation (Fig. 1).
Tetramer stabilization does not inhibit TTR amyloid formation
induced by any of the ATTR ex vivo seeds studied
In our previous study, we report that our specimen obtained
from an ATTR-D38A patient contains type B ATTR amyloid
fibrils made of full-length TTR (3, 13). To rule out the possibil-
ity of pathology-based specificity, we analyzed seeding inhibi-
tion by ligands with seven additional ATTR samples (Fig. 2).
For this assay, we incubated 0.5 mg/ml of recombinant WT
TTR with 30 ng/l of ATTR ex vivo seeds in the presence or
absence of 180Mstabilizers.Wemonitored fibril formation by
quantifying the protein content in the insoluble fraction after
24 h of incubation at 37 °C. As in our ATTR-D38A experi-
ments, we found that the addition of tafamidis or diflunisal did
not reduce the accumulation of insoluble material in the pres-
ence of seeds extracted from any of the other seven ATTR car-
diac specimens. These findings suggest that tetramer stabiliza-
tion by ligands may not be an effective strategy to halt amyloid
seeding under the studied conditions.
T119M-derived stabilization fails to inhibit amyloid seeding
We then evaluated tetramer stabilization by mutagenesis,
analyzing the effect of the T119M TTR variant on amyloid
seeding. This variant exhibits high tetrameric stability
resulting in a significant delay of the onset of hereditary neu-
ropathic ATTR in patients who carry both ttr-V30M and
ttr-T119M genes (5, 14, 15). Although a sample containing 1
mg/ml of recombinant T119M variant remained soluble
after days of incubation at a low pH that causes native TTR to
dissociate (10) (Fig. 3a), the addition of 30 ng/l of ATTR-
D38A ex vivo seeds to 0.5 mg/ml of recombinant T119M did
result in seeded fibril formation (Fig. 3b). Notably, unlike
T119M, the TTR variant T119W,which blocks self-association of
strandH (10), did show a significant decrease in protein fibril for-
mationuponseeding (Fig. 3b).Wealso found that although ex vivo
seeds caused the aggregation of a TTR variant that blocks self-
association of strand F, S85P/E92P, the lag phase was significantly
longer (Fig. 3, b and c). Consistent with our previous work (3),
these findings suggest that blocking self-association of amyloido-
genic TTR segments may be an effective approach to stop fibril
formation when ATTR amyloid seeds are present.
TabFH2 halts amyloid seeding caused by ex vivo seeds
extracted from all ATTR samples evaluated
In a previous study, we developed peptide inhibitors that
were designed to cap the tip of amyloidogenic segments of TTR
in their amyloid state (10). Recently, we have shown that the
optimized peptide inhibitor TabFH2 blocks amyloid seeding
driven by fibrils extracted from the explanted heart of a patient
who carries the hereditary mutation ATTR-D38A (3). Note
that TabFH2 is a mixture of two peptides, TabF2 and TabH2,
which target the two amyloid-driving segments of transthyretin
(3, 10). To better compare the efficacy of the peptide inhibitor
TabFH2 with tafamidis and diflunisal, we evaluated TabFH2
with the same set of assays.We first found that TabFH2 inhibits
Inhibition of amyloid seeding
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TTR aggregation in the absence of ATTR seeds (Fig. 4a). For
this assay, we incubated 1mg/ml of recombinantWTTTRwith
increasing amounts of TabFH2 and monitored protein aggre-
gation for 4 days by absorbance at 400 nm, and visualized the
insoluble fraction by immunodot blot, as described above. In
addition, we analyzed the inhibitory effect of TabFH2 in our
amyloid seeding assays, using the same conditions as in the
preceding experiment (Fig. 1, c–f): we incubated 0.5 mg/ml of
recombinantWTTTRwith 30 ng/l of ATTR-D38A seeds and
TabFH2 at various concentrations, for 24 h (Fig. 4, b–d). We
found that TabFH2 completely inhibits TTR amyloid seeding at
concentrations higher than 180 M with an intermediate effect
at lower doses. Longer incubation resulted in similar results
(Fig. 4e). Altogether, our results indicate that TabFH2 inhibits
TTR aggregationwhen seeded by ex vivo patient amyloid fibrils,
in a dose-dependent manner (Fig. 4).
We next examined the effectiveness of TabFH2 inhibitors in
other pathological cases, by evaluating its inhibitory activity on
our additional ATTR ex vivo samples (Fig. 5). For this assay, we
incubated 0.5mg/ml of recombinantWTTTRwith 30 ng/l of
ATTR ex vivo seeds extracted from a total of 9 patients, in the
presence or absence of 180 or 360 M TabFH2. We monitored
Figure1. Tetramer stabilizers inhibit TTRaggregation in theabsenceof seedsand fail to inhibit amyloid seedingcausedbyATTR-D38Aexvivo seeds.
a and b, inhibition assay of TTR aggregation in the absence of seeds, measured by absorbance at 400 nm. Increasing amounts of diflunisal (a) or tafamidis (b)
were added to 1 mg/ml of recombinant WT TTR and the sample was incubated for 4 days at pH 4.3. Absorbance measured after 4 days of incubation in the
absence of ligandwas considered 100%aggregation because no soluble TTRwas detected. n 3, error bars, S.D. Right insets, full inhibition of TTR aggregation
by diflunisal (a) or tafamidis (b) was confirmed by anti-TTR dot blot of insoluble fractions (IF) collected by centrifugation. c and d, inhibition assay of amyloid
seeding at pH 4.3, monitored by ThT fluorescence. Increasing amounts of diflunisal (c) or tafamidis (d) were added to 0.5 mg/ml of recombinant WT TTR and
ATTR-D38A seeds. All replicates are shown, n 3. a.u., arbitrary units. Insets, anti-TTR dot-blot of insoluble fractions. All samples were spotted onto the same
nitrocellulose membrane and subjected to the same procedure; splicing was needed for presentation purposes. e and f, short-time view of the lag phase of c
and d, respectively. n 3, error bars, S.D. g, protein content quantification of the insoluble fractions collected from c and d, measured by 280 nm absorbance.
AU, absorbance units. Notice that tafamidis at only its highest concentration tested (360 M) results in a significant reduction of ThT signal (d). However, this
reduction does not correlatewith a reduction of protein content in the insoluble fraction (g). Diflunisal treatment did not inhibit amyloid seeding of TTR under
tested conditions (c and g).
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fibril formation by quantifying the protein content in the insol-
uble fraction after 24 h of incubation at 37 °C (Fig. 5a) and
immunodot blot of the insoluble fraction (Fig. 5b). The pres-
ence or absence of protein aggregates was confirmed by EM
(Fig. 5c). A scrambled version of our peptide inhibitor,H1, was
included as a negative control. We found that the efficacy of
TabFH2was dose-dependent, and although its efficiency differs
from sample to sample, for every sample full inhibition was
observed at the highest concentration analyzed (Fig. 5, a–c).
This variability did not correlate with mutational background
of the ex vivo seeds. In contrast, we found an inverse relation-
ship between TabFH2 effectiveness and the amount of TTR
C-term fragments in the ex vivo resuspension (Fig. 5d). The
content of fragmented TTR, present in type A amyloidosis, was
quantified from two independent Western blots using an anti-
body that specifically recognizes TTRC-terminal fragments, as
we previously described (3). Pearson’s correlation coefficient
between amyloid seeding in the presence of 180 M TabFH2
and TTR fragment content was 0.90 (R-square 0.80) indicat-
ing a positive correlation. In addition, we evaluated the effect of
inhibitors on the seeds extracted from an ATTR-V30M patient
(Fig. 5, e and f). As mentioned above, ATTR-V30M is the most
common form of hereditary ATTR that manifests progressive
polyneuropathy and autonomic symptoms (12).We observed a
similar pattern: TabFH2 offers an inhibitory effect, whereas
tafamidis and diflunisal show limited inhibition of seeding (Fig.
5, e and f).
TabFH2 inhibitory activity is tissue independent
Weextracted ex vivo seeds from small quantities of two addi-
tional tissue types to evaluate tissue specificity of TabFH2. We
extracted ATTR seeds from five samples of adipose tissue col-
lected in fat pad biopsies, including one case of WT ATTR and
four cases of hereditary ATTR, and two samples of labial sali-
vary glands from two ATTR-V30M patients (Table 1). Because
biopsy specimens were considerably smaller than the cardiac
tissue samples (30–150 mg versus 1–5 g), we downsized the
amyloid extraction protocol accordingly. Otherwise, the proce-
Figure 2. Tetramer stabilizers do not inhibit amyloid seeding caused by
anyof the cardiac samples analyzed. a, inhibition assay of amyloid seeding
of ex vivo seeds incubatedwith recombinantWT transthyretin in the absence
or presence of 180M tafamidis or 180M diflunisal. After 24 h of incubation
at pH 4.3, the insoluble fractionwas collected, and protein contentwas quan-
tified by absorbance at 280 nm. Consistentwith the results observed in Fig. 1,
the additionof diflunisal or tafamidis does not result in an apparent reduction
of amyloid seeding.AU, absorbanceunits.b, anti-TTRdot-blot of the insoluble
fractions collected from a, shows that tetramer stabilizers do not reduce the
formation of insoluble TTR-derived material when seeded with ATTR ex vivo
fibrils.
Figure 3. Mutational tetramer stabilization does not halt amyloid seed-
ing. a, aggregation assay of 1 mg/ml of nonaggregating recombinant TTR
mutants in the absence of seeds at pH4.3, followedby absorbance at 400 nm.
The assay shows that the T119M and other nonaggregating variants do not
aggregate at pH 4.3 if unseeded. Aggregation of WT transthyretin was con-
sidered as 100%. Right inset, anti-TTR dot blot of insoluble fractions collected
by centrifugation after 4 days of incubation. n 3. Error bars, S.D. b, amyloid
seeding assay of nonaggregating mutants in the presence of ATTR-D38A ex
vivo seeds, monitored by ThT fluorescence at pH 4.3. Notice that T119M does
aggregate when seeded. Right inset, anti-TTR dot-blot of insoluble fractions
collected after 24 h of incubation. All replicates are shown, n  3. a.u., arbi-
trary units. c, short-time view of the lag phase of the amyloid seeding assay
shown in b. n 3. Error bars, S.D. *, p 0.05 and **, p 0.005.
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dure remained as previously described (3). The extraction from
fat pad biopsies produced a very limited amount of insoluble
material. We were therefore forced to reduce the amount of
ex vivo seeds used in amyloid seeding assays to 5 ng/l. Due
to the formation of structurally different species or perhaps a
result of the small amount of seeds that were added to the
assay, the ThT signal was insufficient to draw any conclu-
sion. For this reason, we opted to follow amyloid seeding by
image-based computational quantification of protein aggre-
gates after 24 h of incubation (Fig. 6). We collected images of
the bottom of 96-well plates by optical microscopy using the
Celigo S Imaging system. The images showed the formation
of UV-positive aggregates in those samples that contained ex
vivo seeds and no apparent aggregation in the control sample
(Fig. 6a). The inhibitory effect of TabFH2 was confirmed by
a significant reduction of amyloid conversion at 180 M (Fig.
6b). Together, our results indicate that TabFH2 efficiently
inhibits amyloid seeding caused by WT and mutant ex vivo
seeds in a tissue-independent manner, for the range of tis-
sues we studied.
Figure 4. The anti-amyloid peptide inhibitor TabFH2 inhibits TTR aggregation and amyloid seeding caused by ATTR ex vivo seeds extracted from
ATTR-D38A cardiac tissue. a, inhibition of TTR aggregation by TabFH2 in the absence of seeds, measured by absorbance at 400 nm. Increasing amounts of
TabFH2 were added to 1 mg/ml of recombinant WT TTR and the sample was incubated for 4 days at pH 4.3. Absorbance measured after 4 days of incubation
in the absence of TabFH2 was considered 100% aggregation because no soluble TTR was detected. n  3. Error bars, S.D. Right inset, anti-TTR dot-blot of
insoluble fractions (IF) collected by centrifugation after 4 days of incubation. b, inhibition of amyloid seeding by TabFH2 at pH 4.3, monitored by ThT
fluorescence. Increasing amounts of TabFH2were added to 0.5mg/ml of recombinantWT TTR and 30 ng/l of ATTR-D38A seeds. All replicates are shown, n
4. a.u., arbitrary units. Inset, anti-TTR dot-blot of insoluble fractions collectedby centrifugation after 24 h of incubation. All sampleswere spotted onto the same
nitrocellulosemembrane and subjected to the sameprocedure; splicingwas needed for presentationpurposes. c, short-time viewof the lagphase of the assay
shown inb.n 4. Error bars, S.D. d,protein content quantification of the insoluble fractions collected fromb, measuredby 280nmabsorbance.AU, absorbance
units. Notice that the reductionof ThT fluorescenceobserved inb correlateswith thedecreaseof total protein andTTRcontent in the insoluble fractions, shown
in c and the right inset of b, respectively. e, comparison of inhibition of amyloid seeding by tafamidis, diflunisal, and TabFH2 when incubated for 4 days,
measured by ThT fluorescence. 360M inhibitor was added to 0.5mg/ml of recombinantWT TTR and 30 ng/l of ATTR-D38A seeds. n 3. Error bars, S.D. Inset,
anti-TTR dot-blot of insoluble fractions collected by centrifugation after 4 days of incubation.
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Figure 5. TabFH2 inhibits amyloid seeding causedby ex vivoATTR seeds extracted fromall cardiac extracts studied. a, inhibition of amyloid seedingby
TabFH2 in the presence of cardiac ex vivo seeds,measured by protein content quantification of insoluble fractions. 30 ng/l of ex vivo seeds extracted from the
hearts of eight ATTR patients were added to 0.5 mg/ml of recombinant WT transthyretin in the presence of 0, 180, or 360 M TabFH2. The insoluble fractions
were collected by centrifugation after 24 h of incubation. The insoluble protein content was measured by absorbance at 280 nm. The results show that full
inhibition of amyloid seeding by TabFH2 is achieved at the highest concentration for every ATTR ex vivo sample. n 3. Error bars, S.D. *, p 0.05; **, p 0.005;
***, p 0.0005. b, TTR immunodot blot of insoluble fractions collected by centrifugation from the assay shown in a, with consistent results. The experiment
shown inaandbwasperformed in combinationwith theassay shown inFig. 2; therefore the control sampleswithout seedsare the same.All samples, including
those fromFig. 2, were spotted onto the samenitrocellulosemembrane and subjected to the sameprocedure; splicingwas needed for presentation purposes.
c, electronmicrographs of the samples containing 360M TabFH2 collected from a. These are uncorrected images generated directly from aGatan 2kX2k CCD
camera. Scale bar, 200 nm. d, correlation between amyloid seeding capacity in the presence of 180MTabFH2, and relative quantity of truncated TTR of ex vivo
ATTR seeds. Notice that the presence of truncated TTR facilitates seeding. Truncated TTR content was quantified by ImageJ from two independent Western
blots. Lineal regression and Pearson r were obtained by OriginLab. e, comparison of inhibition of ATTR-V30M amyloid seeding by tafamidis, diflunisal, and
TabFH2, measured by ThT fluorescence. 180 or 360 M inhibitor was added to 0.5 mg/ml of recombinant WT TTR and 30 ng/l of ATTR-V30M seeds. All
replicates are shown, n 4. a.u., arbitrary units. Inset, anti-TTR dot-blot of insoluble fractions collected by centrifugation after 24 h of incubation. f, electron
micrographs of the samples collected from e.
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TabFH2 inhibits amyloid seeding by binding to ATTR fibrils
Our peptide inhibitors were originally designed and opti-
mized to cap the tip of TTR fibrils by binding-strands F andH
(3, 10). To validate our design, we next assessed binding of
TabFH2 to ATTR seeds (Fig. 7). We first immobilized 5 g of
ATTR-D38A seeds on each of eight anti-TTR pre-coated wells.
Binding of ATTR seeds to the bottom of the wells was con-
firmed later by BCA protein assay of unbound material. We
then added increasing amounts of TabFH2 (0–500 M) to pre-
treated wells. After 2 h of incubation, we analyzed the remain-
ing amount of TabFH2 in the sample by HPLC. Anti-TTR pre-
coated wells treated with buffer, but not seeds, were used as
negative control to detect unspecific binding of TabFH2 to the
well. Whereas the majority of TabFH2 remained in the sample
after incubation in negative control wells, most of TabFH2 was
absent when wells were pretreated with ATTR seeds (Fig. 7d).
Our results indicate that the mechanism of action of our pep-
tide inhibitors involves binding to ATTR fibrils.
Discussion
Extensive studies by others have established that ligands such
as tafamidis and diflunisal bind within TTR and stabilize its
tetrameric structure, diminishing its rate of dissociation and
hence its conversion to amyloid fibrils (5–7). The data of Fig. 1,
a and b, confirm the stabilization of TTR by tafamidis and difl-
unisal. Indeed tafamidis has been prescribed for the treatment
of neuropathic ATTR-V30M and ameliorates disease progres-
sion when administered at disease stage I (16–19). Diflunisal
has shown positive neurological effects in ATTR patients at
different stages (9, 20). Despite the stabilization, our results
show that disease-related seeds convert WT TTR into amyloid
fibrils in the presence of these ligands at concentrations that
fully inhibit aggregation of recombinant transthyretin in the
absence of seeds (Figs. 1 and 2) (21, 22). Thus our results offer a
plausible explanation for the reported limited efficacy of
tafamidis over the long term, when administered at late stages,
or in patients with severe cardiac involvement (8, 23, 24). That
TABLE 1
Tissue specimens used for amyloid extraction
A total of 8 cardiac, 5 adipose, and 2 glandular specimens were included in this study. Patients presenting the same TTR variant are indicated by superscripts.
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is, stabilization of tetrameric TTR may be insufficient in situa-
tions in which seeded polymerization dominates rather than de
novo nucleation of TTR seeds.
Genetically stabilizedTTR fails to inhibit seeded fibril forma-
tion. The genetic variant T119M of TTR and its capacity to
delay fibril formation was originally found in an ATTR-V30M
family because of its protective effects; this variant remains sol-
uble at pH 4.3 for weeks, if not months (Fig. 3a) (10, 14, 25).
However, in our experiments, this stabilized variant does not
halt conversion to amyloid in the presence of ex vivo seeds (Fig.
3, b and c). These findings may explain why heterozygous indi-
viduals carrying both the hereditary amyloidogenic ttr-V30M
allele and the stabilizing ttr-T119M allele in time-developed
ATTR (14, 15). In ATTR-V30M/T119M patients, we hypothe-
size that the mutation T119M may delay the progression of
ATTR by reducing de novo nucleation.
The limited effect of TTR tetramer stabilization in our exper-
iments does not contradict the well-established mechanism of
de novo formation of TTR amyloid (26). In our previous study,
we showed that the conversion of TTR to amyloid fibrils
requires the dissociation of tetramers and partial unfolding of
monomers, which takes place as the pH is lowered to 4.3, expos-
ing the adhesive amyloidogenic segments. Themonomeric var-
iant MTTR, which exposes these segments, can be seeded at
physiological pH (3). TTR dissociation and subsequent seeded
or unseeded polymerization may be triggered by a variety of
factors, such as protease cleavage or local pH disturbances.
In our assays, amyloid seeding is also performed at low pH to
weaken the quaternary structure and to lead to tetramer dis-
sociation. Under acidic conditions, the addition of seeds to
recombinant TTR causes acceleration of fibril formation
through seeded polymerization. We reason that this seeded
polymerization results in fibrils that are resilient to disas-
sembly, thereby making the pathway irreversible. Because
the interaction of TTR with the tetramer stabilizers is not
irreversible, the presence of seeds will eventually reduce
Figure 6. Inhibition of amyloid seeding caused by ex vivo ATTR seeds extracted from human fat pad and salivary gland biopsies. a, representative
optical micrographs of aggregates of recombinant WT TTR formed after 24 h of incubation with 5 ng/l of fat-extracted ATTR-WT or gland-extracted ATTR-
V30M1 ex vivo seeds, as visualized on a Celigo S Imaging systemunder bright field andUV channels. Images are composites generated by the Celigo S Imaging
system. Scale bar, 1 mm; all images have the same scale. Note that the addition of TabFH2 results in the reduction of UV-positive aggregates. Three control
samples are included: samples containingonly seeds, recombinantWTTTR aggregates formedafter incubationwith 30ng/l of cardiacATTR-D38A seeds, and
recombinant WT TTR in the absence of seeds (rec.WT). b, UV intensity-based quantification of protein aggregates after 24 h of incubation of recombinant WT
TTRwith ATTR ex vivo seeds extracted from various adipose tissue and salivary gland samples (labeledwith italic a and g, respectively). The presence of 180M
TabFH2 resulted in the inhibition of amyloid seeding for all studied samples. Cyan line and rectangle represent the UV intensity mean  S.D. range in the
absence of seeds, respectively. n 3. Error bars, S.D. *, p 0.05; **, p 0.005; ***, p 0.0005, for the comparison between samples with andwithout TabFH2.
Inhibition of amyloid seeding
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both monomeric and tetrameric pools while generating irre-
versible amyloid fibrils.
Capping of TTR amyloid fibrils by designed peptides is an
effective approach to inhibit TTR fibril seeding. Our results
show that in cases for which stabilization of tetrameric TTR by
ligands may not be fully effective in halting fibril formation
(Figs. 1 and 2), capping of TTR fibrils by designed blockers of
fibril elongation is effective (Figs. 4–6). This may be of special
importance for cardiac ATTR patients, who are often diag-
nosed when manifesting advanced TTR deposition and have
limited treatment options. In the conditions of our experi-
ments, TabFH2 blockers are effective in halting fibril formation
caused by WT ATTR seeds and also by seeds of at least six
disease-related variants extracted from ex vivo cardiac speci-
mens (Fig. 5). Overall, we find that the inhibition of amyloid
seeding by peptide inhibitors is an effective strategy indepen-
dent of pathological variant or tissue (Figs. 5 and 6).
Structure-based inhibition of amyloid aggregation by pep-
tides is an emergent strategy that has shown promising results.
Our structure-based strategy has generated peptide inhibitors
of Tau fibril formation that is associated with Alzheimer’s dis-
ease (27, 28), SEVI amyloid aggregation that enhances HIV
transmission (28), and p53 aggregation associated with certain
types of ovarian cancer (29). In our previous work on inhibition
of TTR, we generated TTR peptide inhibitors that block both
protein aggregation and amyloid seeding catalyzed by ex vivo
ATTR fibrils (3, 10). Moreover, diseased flies showed motor
improvement and a reduction of TTR deposition after treat-
ment with our peptide inhibitors (30). In this study, we expand
the evaluation of peptide inhibitors to question their inhibitory
capacity compared with two tetramer stabilizers and mutagen-
esis-based stabilization. Fig. 8 depicts how we envision the
mechanism by which TabFH2 and tetramer stabilizers inhibit
amyloid seeding and aggregation, respectively. The peptide
inhibitor TabFH2 was previously designed to bind strands F
and H, the two amyloid driving segments of TTR, thereby halt-
ing self-association and further polymerization (3, 10). Other
groups have expanded on our work on the inhibition of TTR
aggregation by impeding self-association of the amyloid-driv-
ing strands F and H of TTR using monoclonal antibodies (31,
32). Our results indicate that the inhibition of amyloid seeding
by peptide inhibitors may represent a potential therapeutic
strategy for ATTR when tetramer stabilization is not sufficient
to halt disease progression.
Experimental procedures
Antibodies
The antibodies used in this study include rabbit anti-human
transthyretin polyclonal antibody (DAKO, Agilent Technolo-
gies; immunodot blots andWestern blots, 1:10,000) and horse-
radish peroxidase-conjugated goat anti-rabbit IgG antibody
(Thermo Fisher Scientific, immune dot blots and Western
blots, 1:5,000). Anti-truncatedTTRwas generously provided by
Gunilla Westermark (labeled as 1898, Western blots, 1:5,000).
Patients and tissuematerials
Twenty-one ATTR patients carrying WT (n  4) or TTR
mutations (n 17) were included in this study (refer to Table 1
for full details). Cardiac tissue specimens were obtained from
several laboratories from explanted hearts or by autopsy. Adi-
pose tissues were obtained from needle biopsy procedures per-
formed at the University Medical Centre Groningen. Salivary
gland tissues were obtained from surgical biopsy procedures
performed at the Hospital Santo Anto´nio in Porto. The UCLA
Office of the Human Research Protection Program granted
exemption from IRB review because all specimens were anony-
mized. These studies abide by the Declaration of Helsinki
principles.
Extraction of amyloid fibrils from tissue samples
Amyloid fibrils were extracted from fresh-frozen human tis-
sue following a previously described protocol (3). In short,
thawed tissue sample, resuspended in 10ml of 0.15 MNaCl, was
minced with a motorized homogenizer and pelleted by centrif-
ugation at 15,000 rpm for 30 min. The pellet was subject to
further cycles of resuspension, homogenization, and centrifu-
gation first with 0.15 M NaCl solution 7 times, followed by dis-
tilled water 3 times. Because there was less starting material for
both adipose tissue and salivary gland specimens, the extraction
protocol was downsized in volume accordingly. The final pellet
was lyophilized, and amyloid content of the extracts was con-
firmed by EM. TTR content of the samples was analyzed by
anti-TTRWestern blotting.
Figure 7. TabFH2binds ATTR ex vivo seeds. Increasing amounts of TabFH2
were added to independent wells pretreated with ATTR seeds (treated with
seeds) or buffer (treated with buffer), and unbound TabFH2 was detected by
reverse-phase chromatography. TabFH2 samples before treatment were
included in the analysis (untreated). a, representative HPLC elution profile for
a TabFH2 concentration of 500M showing two peaks: TabH2 eluting at17
ml and TabF2 eluting at21ml. b, analysis of TabFH2 recovery at all concen-
trations, measured as peak area integrated from HPLC elution profiles. The
graph shows that the recovery of both TabF2 and TabH2 when wells were
pretreated with ATTR seeds was significantly lower than when pretreated
with buffer.
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Purification of recombinant TTR
Recombinant transthyretin was prepared as described previ-
ously (10). To summarize, Escherichia coli cells (Millipore
Rosetta DE3 pLysS Competent Cells) were transformed with a
pET24() vector carrying the sequence for either WT or a
mutant of transthyretin. The expressed recombinant protein
was harvested and purified by nickel affinity chromatography
with a HisTrap column (GE Healthcare). The appropriate frac-
tions were pooled and further purified by size exclusion on a
Superdex 75 gel filtration column (GE Healthcare). Recombi-
nant transthyretin was stored in 10 mM sodium phosphate, pH
7.5, 100 mM KCl, and 1 mM EDTA at20 °C.
Western blotting of tissue extracts
TTR content of tissue extracts was confirmed by Western
blotting as described previously (3). To summarize, equal
amounts of total protein were loaded on a 4–12% NuPAGE
BisTris gel (ThermoFisher Scientific) and separated by gel elec-
trophoresis in denaturing conditions. TTR was detected after
transfer to a nitrocellulose membrane with polyclonal anti-hu-
man transthyretin antibody or anti-truncated TTR antibody
and horseradish peroxidase-conjugated secondary goat anti-
rabbit IgG. SuperSignalTM West Pico Chemiluminescent Sub-
strate (ThermoFisher Scientific) was used according to the
manufacturer’s instructions to visualize TTR content. Trun-
cated TTR content of cardiac seeds was quantified by ImageJ
using two independent Western blots.
Congo red staining and TTR content quantification of adipose
tissue
Abdominal fat smears were made as previously described
(33). Slides were stained with alkaline Congo red (34) and
apple-green birefringence under polarized light were semi-
quantitatively scored as follows: 0 (negative), 1 (min,1% sur-
face area), 2 (little, between 1 and 10%), 3 (moderate, between
10 and 60%), and 4 (abundant,60%). The remaining abdom-
inal fat tissue was weighed and washed. Proteins were resus-
pended with a Tris-guanidinium hydrochloride solution, and
TTR content was measured by ELISA. Briefly, microtiter plates
were coated overnight with the extracts and human native TTR
protein (Abcam, Cambridge, UK), which served as control, in
several dilutions. Detection was done by using rabbit anti-hu-
manTTRpolyclonal antibodies (DAKO,Agilent Technologies)
followed by horseradish peroxidase-conjugated goat anti-rab-
bit IgG antibody (DAKO, Agilent Technologies) and visualized
by a color reaction with TMB ELISA substrate. Plates were
scanned at 450 nm after stopping the reaction with sulfuric
acid.
Peptides
Peptides were synthesized at 97% purity by GL Biochem
(Shanghai) Ltd. (Shanghai, China). Purity andmolecular weight
were confirmed by MALDI-TOF and reversed phase HPLC.
TabFH2 is an equimolar mixture of RRRRHVAHPFV(N-
methyl)EFTE and RRRRSYVTNPTSY(N-methyl)AVT, as pre-
viously described (3). Peptides were dissolved in 0.22 m of
filtered water to 5 mM stock solution. These working solutions
were further diluted prior to use to the final concentration.
Non-seeded TTR aggregation
TTR aggregation assays were done as previously described
(10). Briefly, 1mg/ml of TTR sample in 100mM sodium acetate,
pH 4.3, 100mMKCl, 1mMEDTAwas incubated in the presence
or absence of inhibitor, diflunisal, tafamidis, or TabFH2, at
37 °C for 4 days. TTR aggregation was followed by measuring
sample turbidity at 400 nmand by anti-TTR immunodot blot of
the insoluble fraction.
TTR amyloid-seeding assay
Extracted tissue samples were used to seed the formation of
transthyretin amyloid fibrils following a protocol described
previously (3). In short, extracts were washed twice in 1% SDS
and twice in 10 mM sodium phosphate, pH 7.5, 100 mM KCl, 1
mM EDTA. Next, the extracts were sonicated at minimum
intensity with 5-s pulses for a total of 10 min. Protein concen-
tration of the samples was determined by PierceTM BCA Pro-
tein Assay Kit (ThermoFisher Scientific). Seeding reactions
contained 0.5 mg/ml of recombinant protein, 30 ng/l of car-
Figure 8. Model of TTR amyloid seeding and its inhibition. TTR dissociation provides monomers that are susceptible to nucleation and fibril formation
through self-association of amyloid-driving segments. TTR ligands such as tafamidis or diflunisal stabilize the tetrameric form, decelerating tetramer dissoci-
ation andunseededpolymerization. After fragmentation of fibrils, small fragmentsmay serve as seeds that template fast polymerization. Thepeptide inhibitor
TabFH2 does not affect tetramer stability. Instead, TabFH2 binds to seeds, hindering self-recognition and seeding. Both strategies seem synergistic and could
potentially be used in combination.
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diac extract or in the case of adipose and gland extracts 5 ng/l,
5M thioflavin T, 100mM sodium acetate, pH 4.3, 100mMKCl,
and 1 mM EDTA. The inhibitors mentioned, diflunisal, tafami-
dis, andTabFH2,were added at concentrations described in the
figure legends. Thioflavin T fluorescence emission was mea-
sured at 482 nm with excitation at 440 nm in a FLUOstar
Omega (BMG LabTech) plate reader. Plates were incubated at
37 °C for 24 h with orbital shaking at 700 rpm between mea-
surement points. In all assays, measurements were normalized
by subtracting the initial ThT measurement and considering
the maximum signal as 100%. Protein aggregates were visual-
ized by both bright field and UV and TTR aggregation was
quantified using a Celigo S Imaging system. The insoluble frac-
tion was obtained by centrifuging the sample and resuspending
the pellet in guanidinium hydrochloride. Protein content of the
pellet was determined by measuring absorbance at 280 nm.
Anti-TTR immunodot blot
TTR aggregation was confirmed by immunodot blot as men-
tioned previously (10). After obtaining the insoluble fraction by
centrifugation and resuspension in guanidinium hydrochlo-
ride, 15 l of sample was dotted onto a nitrocellulose mem-
brane (0.2 m, Bio-Rad). TTR content was visualized using
polyclonal rabbit anti-human transthyretin (DAKO), horse-
radish peroxidase-conjugated goat anti-rabbit IgG antibody
(ThermoFisher Scientific), and SuperSignalTM West Pico
Chemiluminescent Substrate (ThermoFisher Scientific).
Transmission electronmicroscopy
Amyloid content of tissue extracts and inhibition of fibril
formation was confirmed by transmission EM. 5 l of sample
was applied to a glow-discharged carbon-coated EM grid
(CF150-Cu, Electron Microscopy Sciences) for 4 min. After
three quick rinses in distilled water, grids were stained with 2%
uranyl acetate for 2 min. Samples were visualized using a T12
Quick CryoEMandCryoET (FEI) transmission electronmicro-
scope using an acceleration voltage of 120 kV equipped with a
Gatan 2,048	 2,048 CCD camera.
Detection of TabFH2 binding to ATTR seeds
TabFH2 binding to ATTR seeds was analyzed by HPLC.
First, ATTR-D38A fibrils were immobilized on anti-TTR pre-
coated well plates (Prealbumin ELISA kit, Abcam) as follows.
50-ml samples containing 0.1 mg/ml of ATTR seeds were
added on each well. Control wells were equally treated with
buffer (10 mM sodium acetate, pH 7.5, 100 mM KCl, 1 mM
EDTA). After 1-h incubation at room temperature, samples
were then removed and wells were washed twice with buffer.
Immobilization of the total amount of fibrils was confirmed by
BCAprotein assay of the remaining sample. 50-ml samples that
contained increasing concentrations of TabFH2 (0–500 mM)
were added to independent wells pretreated with ATTR seeds
or buffer. After an incubation of 2 h at room temperature, sam-
ples were transferred to new tubes and snap frozen until further
analysis. Unbound TabFH2 was detected by chromatography
after 0.10 nm filtration, on a Waters 1525 HPLC System
(SpectraLab), with a Proto 300 C18 5-mm 250	 4.6-mm ana-
lytical reverse phase column (Higgins Analytical); flow rate 
1.0ml/min; solvents: A 0.1%TFA inwater, andB 0.1%TFA
in acetonitrile. The column was equilibrated with 10% B for 5
min, followed by a gradient from 10 to 60% B in 30 min, and a
2-min wash at 95% B. TabFH2 eluted in two peaks after 17
and 20 min from the start. Peaks were integrated by Breeze2
software and Prism was used for graphing.
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